Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
| 46.27 Delayed Data As of Sep 17 |  -1.04 / -2.20%Today’s Change | 38.40 Today|||52-Week Range 73.40 | -25.11% Year-to-Date |
Latest ENTA News | Press Releases
| Enanta initiates early-stage NASH study with EDP-297 Sep 14 / Seeking Alpha - Paid Partner Content | Enanta Pharma reports encouraging data on HBV and NASH candidates Aug 28 / Seeking Alpha - Paid Partner Content |
| Fortress Reports Positive Data And Other News: The Good, Bad And Ugly Of Biopharma Aug 31 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 47.37 |
| Today’s open | 46.99 |
| Day’s range | 45.94 - 47.71 |
| Volume | 136,455 |
| Average volume (3 months) | 161,976 |
| Market cap | $930.9M |
Data as of 4:00pm ET, 09/17/2020
Growth & Valuation
| Earnings growth (last year) | -36.62% |
| Earnings growth (this year) | -140.08% |
| Earnings growth (next 5 years) | -83.30% |
| Revenue growth (last year) | -0.69% |
| P/E ratio | 462.7 |
| Price/Sales | 6.14 |
| Price/Book | 1.98 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AMPHAmphastar Pharmaceut... | -0.04 | -0.21% |
| HSKAHeska Corp | -1.38 | -1.41% |
| ---- | ||
| KRYSKrystal Biotech Inc | +0.05 | +0.11% |
Data as of 3:59pm ET, 09/17/2020
Financials
| Next reporting date | November 30, 2020 |
| EPS forecast (this quarter) | -$0.54 |
| Annual revenue (last year) | $205.2M |
| Annual profit (last year) | $46.4M |
| Net profit margin | 22.60% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Watertown, Massachusetts |
Forecasts
